Overview
- Exact Sciences shareholders will receive $105 per share in cash, valuing the equity at about $21 billion, or up to $23 billion including roughly $1.8 billion in net debt.
- The deal adds Cologuard colorectal screening and Oncotype DX breast cancer tests to Abbott’s diagnostics lineup to accelerate expansion into cancer screening and offset weaker COVID-19 test revenue.
- Exact Sciences projects more than $3 billion in 2025 revenue with high-teens organic growth, and Abbott forecasts combined diagnostics sales topping $12 billion annually after closing.
- Markets moved on the news, with Exact Sciences shares up roughly 17–23% in early trading as Abbott stock slipped about 1–2%.
- Exact will maintain its Madison, Wisconsin presence, and CEO Kevin Conroy will remain in an advisory role to support the transition.